Most Read Articles
Roshini Claire Anthony, 4 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 5 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
3 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.

Obesity ups risk of acute chronic liver failure in decompensated cirrhosis patients

26 Aug 2018
A higher than normal BMI is often a risk factor for many long-term health problems such as diabetes, hypertension, joint, heart and even liver problems.

In patients with decompensated cirrhosis, class III obesity increases the risk of acute on chronic liver failure (ACLF) development, a recent study has found.

Drawing from the United Network for Organ Sharing database, researchers identified 100,382 eligible participants, of whom 63,712 were nonobese (mean age 53.10±11.0 years; 62.9 percent male), 32,605 were class I–II obese (mean age 54.6±8.9 years; 63.8 percent male) and 4,065 were class III obese (mean age 52.6±9.1 years; 53.7 percent male).

At the time of liver transplantation, 7,630 patients had ACLF, of whom 4,688 were nonobese, 2,587 were class I–II obese and 355 were class III obese. Kaplan-Meier analysis revealed that those with class III obesity were significantly more likely to develop ACLF (p<0.001).

Multivariable Cox proportional hazards regression analysis further confirmed that class III obesity was a significant risk factor for ACLF (hazard ratio [HR], 1.24; 95 percent CI, 1.09–1.41; p<0.0001). The same was true for class I–II obesity (HR, 1.12; 1.05–1.19; p<0.001).

Other factors that significantly correlated with ACLF included older age, hepatitis C infection, ascites, alcoholic liver disease and hepatic encephalopathy.

Obesity was also associated with organ failure. While renal insufficiency was comparable between patient groups, renal failure was progressively more prevalent with increasing obesity class (p<0.001), and coagulation failure was most common in patients with class I–II obesity (51.3 percent). In contrast, liver failure as a component of ACLF was inversely correlated with obesity class.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 5 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
3 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.